Dietetics and Clinical Nutrition Unit, IRCCS-Policlinic Hospital San Martino, Genoa, Italy.
Dietetics and Clinical Nutrition Unit, IRCCS-Policlinic Hospital San Martino, Genoa, Italy; Experimental Medicine Department, Medical Pathophysiology, Food Science and Endocrinology Section, Food Science and Human Nutrition Research Unit, Sapienza University, Rome, Italy.
Nutrition. 2021 Sep;89:111236. doi: 10.1016/j.nut.2021.111236. Epub 2021 Mar 7.
Our primary objective was to explore the effect of a eucaloric ketogenic diet (EKD) on mortality, admission to the intensive care unit, and need for non-invasive ventilation in hospitalized patients with COronaVIrus Disease 19 (COVID-19), in comparison to a eucaloric standard diet. Secondary objectives were verification of the safety and feasibility of the diet and its effects on inflammatory parameters, particularly interleukin-6.
The study is a retrospective analysis of 34 patients fed with an EKD in comparison to 68 patients fed with a eucaloric standard diet, selected and matched using propensity scores 1:2 to avoid the confounding effect of interfering variables. Our hypothesis was that an EKD would reduce mortality, admission to the intensive care unit, and need for non-invasive ventilation in patients with COVID-19.
The preliminary multivariate analysis showed a statistically significant difference in survival (P = 0.046) and need for the intensive care unit (P = 0.049) for the EKD compared with a eucaloric standard diet. Even considering the EKD start day as a time-dependent variable, the results maintain a positive trend for application of the diet, and it is not possible to reject the null hypothesis (P < 0.05). Interleukin-6 concentrations between t0 and t7 (7 d after the beginning of the diet) in the ketogenic nutrition group show a trend that is almost significant (P = 0.062). The EKD was safe and no adverse events were observed.
These results show a possible therapeutic role of an EKD in the clinical management of COVID-19. Currently, a prospective controlled randomized trial is running to confirm these preliminary data.
本研究旨在探讨生酮饮食(EKD)对因 2019 年冠状病毒病(COVID-19)住院患者死亡率、入住重症监护病房(ICU)和需要无创通气的影响,并与生酮标准饮食(Euc KD)进行比较。次要目的是验证该饮食的安全性和可行性及其对炎症参数(特别是白细胞介素 6)的影响。
本研究是对 34 例接受 EKD 治疗的患者与 68 例接受 Euc KD 治疗的患者进行的回顾性分析,通过倾向评分 1:2 进行选择和匹配,以避免混杂因素的影响。我们的假设是 EKD 可降低 COVID-19 患者的死亡率、入住 ICU 和需要无创通气的几率。
初步多变量分析显示,EKD 组与 Euc KD 组相比,在生存率(P=0.046)和入住 ICU 的需求(P=0.049)方面存在统计学差异。即使将 EKD 开始日视为时间依赖性变量,结果仍然显示该饮食的应用呈积极趋势,不能拒绝零假设(P<0.05)。在生酮营养组中,从 t0 到 t7(开始饮食后 7 天)的白细胞介素 6 浓度呈显著趋势(P=0.062)。EKD 是安全的,未观察到不良事件。
这些结果表明 EKD 可能在 COVID-19 的临床管理中具有治疗作用。目前,正在进行一项前瞻性对照随机试验以确认这些初步数据。